pH to present 3 RWE posters at ASH next week

The 59th ASH Annual Meeting & Exposition is a premier event in the malignant and non-malignant haematology calendar. We’re proud to have 3 posters at ASH next week – showing the ever increasing value of Real World Evidence to the scientific community. Visit the links below to view our accepted abstracts:-
Age (≤75 years) and Not Choice of First-line Therapy Improves Overall Survival in Transplant Ineligible NDMM Patients: Results from a Large UK Real-World Dataset https://ash.confex.com/ash/2017/webprogram/Paper104582.html
Inferior Clinical Outcomes with Fixed-Duration Therapy for Transplant-Ineligible Myeloma Patients: UK Real-World Data in Comparison with the FIRST Trial (MM-020)
https://ash.confex.com/ash/2017/webprogram/Paper102232.html
The TARGET UK Study: real-world evidence of molecular response to tyrosine kinase inhibitors supports European LeukemiaNet 2013 recommendations for the management of Chronic Myeloid Leukemia
https://ash.confex.com/ash/2017/webprogram/Paper105390.html